Table 2 Baseline Demographics and Clinical Characteristics
From: The potential role of appetite in predicting weight changes during treatment with olanzapine
Parameter | Study 1 (N = 68) | Study 2 (N = 65) | Study 3 (N = 50) | Study 4 (N = 622) |
|---|---|---|---|---|
Age (years), mean (SD) | 43.5 (9.5) | 38.7 (12.2) | 38.5 (12.0) | 35.6 (12.2) |
Male gender, n (%) | 45 (66.2) | 33 (50.8) | 120 (60.3) | 269 (43.2) |
Ethnicity, n (%) | ||||
   White | 27 (39.7) | 36 (55.4) | 87 (43.7) | 148 (23.8) |
   African American | 34 (50.0) | 4 (6.2) | 16 (8.0) | 0 |
   East/Southeast Asian | 1 (1.5) | 1 (1.5) | 39 (19.6) | 369 (59.3) |
   Native American | 0 | 0 | 0 | 0 |
   Hispanic | 4 (5.9) | 23 (35.4) | 52 (26.1) | 83 (13.3) |
   West Asian | 0 | 0 | 4 (2.0) | 1 (0.2) |
   Other | 2 (2.9) | 1 (1.5) | 0 | 0 |
   Native American/First Nation | 0 | 0 | 1 (0.5) | 0 |
   Missing | 0 | 0 | 0 | 21 (3.4) |
Weight (kg), mean (SD) | 86.3 (16.8) | 81.2 (17.0) | 77.5 (16.6) | 64.1 (12.5) |
BMI, mean (SD) | 28.7 (5.1) | 28.3 (4.8) | 27.1 (4.7) | 23.2 (3.9) |
Appetite, mean (SD) | EBA Item #1: 1.5 (1.1)a | PARS: 65.7 (19.2) | EI-Cognitive Restraint: 7.6 (5.2)b | EAS 1: 1.6 (1.2)c |
| Â | EBA Item #2: 1.6 (1.1)a | Â | EI-Disinhibition: 8.7 (4.6)b | EAS 2: 1.6 (1.1)c |
| Â | EBA Item #3: 1.1 (1.2)a | Â | EI-Hunger: 7.9 (4.5)b | EAS 5: 2.3 (1.2)d |
| Â | EBA Item #4: 0.9 (1.1)a | Â | FCI Total: 65.4 (20.1) | EAS 6: 1.3 (1.2)f |
| Â | EBA Item #5: 2.5 (1.0)a | Â | Â | EAS 7: 1.2 (1.2)f |
| Â | EBA Item #6: 0.9 (1.2)a | Â | Â | EAS 8: 0.7 (0.9)f |
| Â | EBA Item #7: 0.9 (1.2)a | Â | Â | EAS 9: 0.6 (0.9)f |
| Â | EBA Item #8: 0.4 (0.9)a | Â | Â | Â |
| Â | EBA Item #9: 0.1 (0.3)a | Â | Â | Â |